[go: up one dir, main page]

BR0004538A - Combinação eficaz para o tratamento da impotência - Google Patents

Combinação eficaz para o tratamento da impotência

Info

Publication number
BR0004538A
BR0004538A BR0004538-1A BR0004538A BR0004538A BR 0004538 A BR0004538 A BR 0004538A BR 0004538 A BR0004538 A BR 0004538A BR 0004538 A BR0004538 A BR 0004538A
Authority
BR
Brazil
Prior art keywords
treatment
impotence
effective combination
compound selected
compounds
Prior art date
Application number
BR0004538-1A
Other languages
English (en)
Inventor
Murray Craig Maytom
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0004538A publication Critical patent/BR0004538A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMBINAçãO EFICAZ PARA O TRATAMENTO DA IMPOTêNCIA"<D>. A presente invenção refere-se com o tratamento da disfunção eretil utilizando uma combinação de (1) um composto selecionado a partir dos indutores da abertura de canais de potássio e de (2) um composto selecionado a partir dos compostos que aumentam os teores de cGMP. O sildenafil ou um seu sal farmaceuticamente aceitável é preferido como o indutor do acréscimo dos teores de cGMP PDE. Estão também incluídas composições e kits compreendendo tais compostos de tratamento da impotência.
BR0004538-1A 1999-09-30 2000-09-29 Combinação eficaz para o tratamento da impotência BR0004538A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15675099P 1999-09-30 1999-09-30

Publications (1)

Publication Number Publication Date
BR0004538A true BR0004538A (pt) 2001-04-17

Family

ID=22560924

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0004538-1A BR0004538A (pt) 1999-09-30 2000-09-29 Combinação eficaz para o tratamento da impotência

Country Status (4)

Country Link
US (1) US6436944B1 (pt)
EP (1) EP1090644A3 (pt)
BR (1) BR0004538A (pt)
CA (1) CA2321378A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
EP1365794A2 (en) * 2000-07-21 2003-12-03 Lue, Tom Prevention and treatment of sexual arousal disorders
US6951435B1 (en) 2002-08-02 2005-10-04 Global Trade Enterprises, Ltd. Method and apparatus for forming new and retrofit detectable warning surfaces
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
US7037257B1 (en) 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
ES2539969T3 (es) 2004-08-25 2015-07-07 Essentialis, Inc. Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
US20090062264A1 (en) * 2007-07-02 2009-03-05 Cowen Neil M Salts of potassium atp channel openers and uses thereof
US9662391B2 (en) 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US9560967B2 (en) 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US9649469B2 (en) 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
WO2011156405A2 (en) * 2010-06-07 2011-12-15 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
RU2643671C1 (ru) * 2016-12-13 2018-02-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ретинальной ишемии-реперфузии миноксидилом в эксперименте

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
CA2123312A1 (en) * 1991-12-23 1993-07-08 Pharmacia & Upjohn Company A potent drug for treatment of erectile dysfunction
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
FR2726770B1 (fr) * 1994-11-16 1997-01-31 Lhd Lab Hygiene Dietetique Dispositif d'administration transdermique de medicaments pour le traitement de l'impuissance erectile masculine
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
AU4696499A (en) * 1998-06-19 2000-01-05 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
PL196955B1 (pl) * 1998-12-04 2008-02-29 Bristol Myers Squibb Co Pochodna 3-podstawionego -4-arylochinolin -2-onu jako modulator kanałów potasowych, jej zastosowanie i kompozycja farmaceutyczna
US6214849B1 (en) * 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans

Also Published As

Publication number Publication date
US6436944B1 (en) 2002-08-20
CA2321378A1 (en) 2001-03-30
EP1090644A2 (en) 2001-04-11
EP1090644A3 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
BR0004538A (pt) Combinação eficaz para o tratamento da impotência
BR9813699A (pt) Combinação eficaz para o tratamento da impotência
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
MY126917A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
DE60216745D1 (de) Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
TWI264437B (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
BRPI0411864A (pt) combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas
ATE456957T1 (de) Methode und zusammensetzung zur behandlung diabetischer neuropathie
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
PT1109814E (pt) 5-heterociclil pirazol¬4,3-d|pirimidina-7-onas para o tratamento da disfuncao erectil masculina
BRPI0211025B8 (pt) um novo composto para o tratamento da impotência
ATE302011T1 (de) PONAZURIL ZUR BEHANDLUNG VON DURCH COCCIDIA NEUROLOGISCHEN UND ßABORTIGENICß VERURSACHTEN ERKRANKUNGEN
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
ATE310521T1 (de) Praziquantel zusammensetzungen zur behandlung von krankheiten verursacht durch kokzidien
DE602004025119D1 (de) Neue derivate von 4,4&#39;-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen
ATE320797T1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ES2183500T3 (es) Nuevos compuestos y composiciones farmaceuticas que los contienen.
BR0206322A (pt) Derivados de pirrolopiridinona substituìdos úteis como inibidores de fosfodiesterase

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.